A detailed history of Davenport & CO LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Davenport & CO LLC holds 2,284,435 shares of BMY stock, worth $132 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares
2,284,435
Previous 2,296,146 0.51%
Holding current value
$132 Million
Previous $95.4 Million 23.97%
% of portfolio
0.7%
Previous 0.6%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$39.66 - $51.75 $464,458 - $606,044
-11,711 Reduced 0.51%
2,284,435 $118 Million
Q2 2024

Aug 06, 2024

SELL
$40.25 - $52.99 $3.6 Million - $4.73 Million
-89,337 Reduced 3.75%
2,296,146 $95.4 Million
Q1 2024

May 03, 2024

BUY
$47.98 - $54.4 $10.4 Million - $11.7 Million
215,717 Added 9.94%
2,385,483 $129 Million
Q4 2023

Jan 23, 2024

BUY
$48.48 - $57.85 $11.4 Million - $13.5 Million
234,123 Added 12.1%
2,169,766 $111 Million
Q3 2023

Oct 17, 2023

BUY
$57.89 - $64.73 $38.5 Million - $43 Million
664,626 Added 52.29%
1,935,643 $112 Million
Q2 2023

Jul 20, 2023

BUY
$63.71 - $70.74 $64 Million - $71 Million
1,004,088 Added 376.16%
1,271,017 $81.3 Million
Q1 2023

Apr 27, 2023

SELL
$65.71 - $74.53 $403,787 - $457,986
-6,145 Reduced 2.25%
266,929 $18.5 Million
Q4 2022

Jan 20, 2023

SELL
$68.48 - $81.09 $1.15 Million - $1.36 Million
-16,790 Reduced 5.79%
273,074 $0
Q3 2022

Oct 11, 2022

SELL
$0.13 - $76.84 $4,543 - $2.69 Million
-34,952 Reduced 10.76%
289,864 $20.6 Million
Q2 2022

Jul 18, 2022

SELL
$72.62 - $79.98 $1.49 Million - $1.64 Million
-20,515 Reduced 5.94%
324,816 $25 Million
Q1 2022

May 02, 2022

SELL
$61.48 - $73.72 $2 Million - $2.39 Million
-32,451 Reduced 8.59%
345,331 $25.2 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $59.9 Million - $69.8 Million
-1,116,601 Reduced 74.72%
377,782 $23.6 Million
Q3 2021

Oct 14, 2021

BUY
$59.17 - $69.31 $3.64 Million - $4.26 Million
61,521 Added 4.29%
1,494,383 $88.4 Million
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $2.2 Million - $2.4 Million
35,560 Added 2.54%
1,432,862 $95.7 Million
Q1 2021

Apr 28, 2021

SELL
$59.34 - $66.74 $580,463 - $652,850
-9,782 Reduced 0.7%
1,397,302 $88.2 Million
Q4 2020

Jan 13, 2021

SELL
$57.74 - $65.43 $427,333 - $484,247
-7,401 Reduced 0.52%
1,407,084 $87.3 Million
Q3 2020

Oct 15, 2020

SELL
$57.43 - $63.64 $1.96 Million - $2.18 Million
-34,183 Reduced 2.36%
1,414,485 $85.3 Million
Q2 2020

Jul 28, 2020

SELL
$54.82 - $64.09 $746,100 - $872,264
-13,610 Reduced 0.93%
1,448,668 $85.2 Million
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $24.9 Million - $36.2 Million
-536,718 Reduced 26.85%
1,462,278 $81.5 Million
Q4 2019

Jan 22, 2020

BUY
$49.21 - $64.19 $3.22 Million - $4.2 Million
65,483 Added 3.39%
1,998,996 $128 Million
Q3 2019

Oct 16, 2019

SELL
$42.77 - $50.71 $843,595 - $1 Million
-19,724 Reduced 1.01%
1,933,513 $89.7 Million
Q2 2019

Jul 10, 2019

BUY
$44.62 - $49.34 $21.4 Million - $23.7 Million
479,370 Added 32.52%
1,953,237 $88.6 Million
Q1 2019

Apr 17, 2019

BUY
$45.12 - $53.8 $4.57 Million - $5.45 Million
101,268 Added 7.38%
1,473,867 $70.3 Million
Q4 2018

Jan 28, 2019

SELL
$48.76 - $63.23 $476,238 - $617,567
-9,767 Reduced 0.71%
1,372,599 $71.3 Million
Q3 2018

Oct 11, 2018

BUY
$55.19 - $62.25 $694,510 - $783,354
12,584 Added 0.92%
1,382,366 $85.8 Million
Q2 2018

Jul 09, 2018

BUY
$50.53 - $62.98 $10.1 Million - $12.6 Million
200,804 Added 17.18%
1,369,782 $75.8 Million
Q1 2018

Apr 04, 2018

SELL
$59.92 - $68.98 $1.1 Million - $1.26 Million
-18,304 Reduced 1.54%
1,168,978 $73.9 Billion
Q4 2017

Jan 17, 2018

SELL
$59.94 - $65.35 $1.73 Million - $1.89 Million
-28,943 Reduced 2.38%
1,187,282 $72.8 Billion
Q3 2017

Oct 12, 2017

BUY
$55.23 - $63.74 $67.2 Million - $77.5 Million
1,216,225
1,216,225 $77.5 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Davenport & CO LLC Portfolio

Follow Davenport & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.